In the months following the carbapenem-resistant enterobacteriaceae outbreak linked to duodenoscopes, medical device manufacturer Olympus has repeatedly come under fire for its response to the outbreak.
A new study found that almost half of U.S. hospitals are failing to take the required steps to prevent C. diff infections, which kill nearly 30,000 people annually.
Recent carbapenem-resistant enterobacteriaceae (CRE) outbreaks at two Los Angeles hospitals have raised serious questions regarding reprocessing procedures tied to duodenoscopes and the risks patients face during endoscopic retrograde cholangiopancreatography (ERCP) procedures.
